Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 801–900 of 1,006
Mind the GAP: Wnt Steps onto the mTORC1 Train
Choo, A. Y., Roux, P. P., & Blenis, J. (2006) · Cell · doi:10.1016/j.cell.2006.08.025 · Cited by 43
“…which negatively regulates the activity of GSK3. instance, Akt phosphorylates TSC2 at Ser939 and Thr1462, and mutation of these sites to Ala residues inhibits the ability of PI3K/Akt (stimulated by growth factors) to activate S6K1, a downstream effector of mTORC1 (Shaw and Cantley, 2006).”
BackgroundSilencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition
Jin, H.-O., HONG, S. I., Woo, S.-H., Lee, J.-H., Choe, T.-B., Kim, E.-K., Noh, W.-C., Lee, J.-K., Hong, S.-I., Kim, J. M., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.63 · Cited by 43
“mTOR is constitutively activated in a variety of human cancers, including ovarian, pancreatic, as well as lung carcinoma.(7) Thus, mTOR signaling networks have emerged as attractive targets in novel therapeutic anticancer strategies.”
BackgroundCooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic Mice
Blando, J. M., Carbajal, S., Abel, E. L., Beltrán, L., Conti, C. J., Fischer, S. M., & DiGiovanni, J. (2011) · Neoplasia · doi:10.1593/neo.101388 · Cited by 45
Alao, J. P., Stavropoulou, A. V., Lam, E. W. ‐., & Coombes, R. C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-40 · Cited by 49
van Maldegem, A. M., Bovée, J. V. M. G., Peterse, E., Hogendoorn, P. C. W., & Gelderblom, H. A. J. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.009 · Cited by 44
“The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase which is critical in many cellular processes such as cell proliferation and survival [41].”
BackgroundZhu, Y., & Lu, M. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9306 · Cited by 46
“The PI3K pathway has a pivotal role in cell growth, proliferation and survival (26), and is upregulated in a number of different types of cancer (27).”
Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
Chen, Z., Wang, C., Dong, H., Wang, X., Gao, F., Zhang, S., & Zhang, X. (2020) · Molecular Medicine · doi:10.1186/s10020-020-0139-5 · Cited by 46
Wang, X., Xue, B., Zhang, Y., Guo, G., Duan, X., & Dou, D. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03684-x · Cited by 44
Niu, H., Wang, J., Li, H., & He, P. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-28 · Cited by 47
Giordano, A., Romano, S., Mallardo, M., D'Angelillo, A., Calì, G., Corcione, N., Ferraro, P., & Romano, M. F. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn079 · Cited by 48
“It is noteworthy that all these signalling kinases drive biochemical networks that directly regulate the expression of genes responsible for cell cycle progression.(41) In accordance with this finding, we found that the expression of cyclin D1 was enhanced in FK506 cultures.”
BackgroundK-Ras Lys-42 is crucial for its signaling, cell migration, and invasion
Choi, B. H., Philips, M. R., Chen, Y., Lu, L., & Dai, W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003723 · Cited by 42
“Ras proteins are membrane-anchored GTPases that participate in multiple signal cascades, mediating numerous biological processes (2, 5, 6).”
BackgroundKnowledge-Based Analysis for Detecting Key Signaling Events from Time-Series Phosphoproteomics Data
Yang, P., Zheng, X., Jayaswal, V., Hu, G., Yang, J. Y. H., & Jothi, R. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004403 · Cited by 44
Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells
Ou, C., Hsu, S., Hsieh, Y.-H., Tsou, W.-L., Chuang, T., Liu, J., & Kao, M. (2008) · Carcinogenesis · doi:10.1093/carcin/bgm263 · Cited by 43
“mTOR is a 289 kDa phosphoinositide kinase-related serine/threonine kinase ( 40 ).”
BackgroundCD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1α/CXCR4 axis
Huang, A.-F., Chen, M.-W., Huang, S.-M., Kao, C.-L., Lai, H., & Chan, J. Y. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-115 · Cited by 42
“These data demonstrated CD164 overexpression upregulates the SDF-1 α /CXCR4 complex and activates downstream PI3K/Akt signaling The PI3 kinase/Akt pathway is commonly dysregulated in human cancers and functions in such processes as proliferation, survival and motility [21-23].”
A Systematic Review on Antitumor Agents with 1, 3, 5-triazines
Liu, B. (2015) · Medicinal Chemistry · doi:10.4172/2161-0444.1000255 · Cited by 49
Mao, Y., Hopkins, D. L., Zhang, Y., Li, P., Zhu, L., Dong, P., Liang, R., Dai, J., Wang, X., & Luo, X. (2016) · Meat Science · doi:10.1016/j.meatsci.2016.03.028 · Cited by 45
Energy sensing pathways: Bridging type 2 diabetes and colorectal cancer?
Yang, J., Nishihara, R., Zhang, X., Ogino, S., & Qian, Z. R. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.04.012 · Cited by 44
“High nutrition will lead to mTORC1 activation because of the loss of PRKA inhibition [25].”
BackgroundLi, Y., Kong, X., Xuan, L., Wang, Z., & Huang, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16946 · Cited by 43
Immunometabolism shapes B cell fate and functions
Fu, Y. L., Wang, L., Yu, B., Xu, D., & Chu, Y. (2022) · Immunology · doi:10.1111/imm.13499 · Cited by 47
Agnihotri, S., Gugel, I., Remke, M., Bornemann, A., Pantazis, G., Mack, S. C., Shih, D. J. H., Singh, S. K., Sabha, N., Taylor, M. D., et al. (2014) · Journal of neurosurgery · doi:10.3171/2014.6.jns131433 · Cited by 45
Danielsen, S. A., Lind, G. E., Bjørnslett, M., Meling, G. I., Rognum, T. O., Heim, S., & Lothe, R. A. (2008) · Human Mutation · doi:10.1002/humu.20860 · Cited by 41
“Somatic mutations of PTEN are among the most common aberrations in human cancer [Shaw and Cantley, 2006], and have been reported at various frequencies in a number of human cancer types, e.g. endometrial, brain, and prostate cancer [Ali et al., 1999; Sansal and Sellers, 2004].”
Current and Emerging Treatments for Chronic Lymphocytic Leukaemia
Robak, T., Jamroziak, K., & Robak, P. J. (2009) · Drugs · doi:10.2165/11319270-000000000-00000 · Cited by 48
“The PI3K/Akt pathway is activated in haematological malignancies by several upstream proteins, such as Ras, TCL1, Bcr-Abl and membrane receptor tyrosine kinases.([201]) Therefore, a significant effort has been made in recent years to define and develop specific inhibitors of this pathway.”
BackgroundGately, K. A., Al-Alao, B. S., Dhillon, T., Mauri, F. A., Cuffe, S. D., Seckl, M. J., & O'Byrne, K. J. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.012 · Cited by 44
Dhillon, S. (2013) · Drugs · doi:10.1007/s40265-013-0034-2 · Cited by 47
“S6K1 and 4EBP1 are thought to control the translation of several growth genes (including hypoxia-inducible factor [HIF]-1a), which drive processes such as cell growth, angiogenesis and glycolysis that contribute to enhanced tumourigenesis [24].”
BackgroundKim, A., Yim, N., & Yeul, J. (2013) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-13-233 · Cited by 42
Stein, A. M., Wang, W., Carter, A. A., Chiparus, O., Hollaender, N., Kim, H., Motzer, R. J., & Sarr, C. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-311 · Cited by 45
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100475 · Cited by 41
“The PI3K/mTOR pathway is universally activated in cancer [38-49].”
BackgroundVascular mTOR-dependent mechanisms linking the control of aging to Alzheimer's disease
Galvan, V., & Hart, M. J. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.010 · Cited by 40
Hensler, M., Vančurová, I., Becht, É., Palata, O., Strnad, P., Tesařová, P., Čabiňaková, M., Švec, D., Kubista, M., Bartůňková, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1102827 · Cited by 41
“PIP3 is an important second messenger in tumorogenesis that activates Akt and other signaling molecules involved in a variety of cellular events, such as survival, proliferation, cell motility, and invasion.(38)”
BackgroundMolecular and functional interactions between AKT and SOX2 in breast carcinoma
Schaefer, T., Wang, H., Mir, P., Konantz, M., Pereboom, T. C., Paczulla, A., Merz, B., Fehm, T. N., Perner, S., Rothfuss, O. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6183 · Cited by 41
Okoye, I., Namdar, A., Xu, L., Crux, N. B., & Elahi, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21003 · Cited by 43
Wang, B., Zhou, T., Nie, C., Wan, D., & Zheng, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.091 · Cited by 42
Zeng, B., Liu, L., Liao, X., Zhang, C., & Ruan, H. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.05.003 · Cited by 43
Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
Mrakovcic, M., & Fröhlich, L. F. (2019) · Cancers · doi:10.3390/cancers12010109 · Cited by 43
Wang, F., Wang, W., Lu, L., Xie, Y., Yan, J., Chen, Y., Di, C., Gan, L., Si, J., Zhang, H., et al. (2020) · Oncology Reports · doi:10.3892/or.2020.7682 · Cited by 45
Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth
Zhang, Y., Zhang, C., Li, J., Jiang, M., Guo, S., Yang, G., Zhang, L., Wang, F., Yi, S., Wang, J., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00897-1 · Cited by 46
Wu, S.-Y., Sung, P., Chang, Y.-L., Pan, S., & Teng, C. (2015) · BioMed Research International · doi:10.1155/2015/738241 · Cited by 41
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Alvarado, Y., Mita, M. M., Vemulapalli, S., Mahalingam, D., & Mita, A. C. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0178-5 · Cited by 44
Brown, V. I., Seif, A. E., Reid, G. S. D., Teachey, D. T., & Grupp, S. A. (2008) · Immunologic Research · doi:10.1007/s12026-008-8038-9 · Cited by 44
P53 suppresses ribonucleotide reductase via inhibiting mTORC1
He, Z., Hu, X., Liu, W., Dorrance, A. M., Garzon, R., Houghton, P. J., & Shen, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17440 · Cited by 43
Mechanisms of Disease: genetic predictors of response to treatment in brain tumors
Collins, V. P. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0820 · Cited by 43
High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma
Ahmed, M., Hussain, A. R., Bavi, P. P., Ahmed, S. O., Al-Sobhi, S. S., Al‐Dayel, F., Shahab Uddin, M. S., & Al-Kuraya, K. S. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu051 · Cited by 41
“P70S6, once phosphorylated, lead to formation of the eIF4F translation initiation complex (47) that is necessary for the maintenance of malignant phenotype of cancer cells (48).”
BackgroundJiang, Y., Yu, K., Bao, J., Peng, W.-T., & Shao, Z. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0092 · Cited by 43
Oleanolic acid induces autophagic death in human gastric cancer cells in vitro and in vivo
Nie, H., Wang, Y., Qin, Y., & Gong, X.-G. (2016) · Cell Biology International · doi:10.1002/cbin.10612 · Cited by 41
“Constitutive activation of mTOR by oncogenic signalling via PI3K/AKT or ERK/p38 MAPK in cancer cells supports the tumour suppressive function of autophagy (Shaw and Cantley, 2006; Cairns et al., 2011).”
BackgroundProcaccia, S., Ordan, M., Cohen, I., Bendetz-Nezer, S., & Seger, R. (2017) · Scientific Reports · doi:10.1038/srep43078 · Cited by 40
Arai, C., Yoshizaki, K., Miyazaki, K., Saito, K., Yamada, A., Han, X. M., Funada, K., Fukumoto, E., Haruyama, N., Iwamoto, T., et al. (2017) · Scientific Reports · doi:10.1038/srep45181 · Cited by 44
Zhao, C.-X., Zhu, W., Ba, Z., Xu, H., Liu, W., Zhu, B., Wang, L., Song, Y., Yuan, S., & Ren, C. (2018) · Europe PMC (PubMed Central) · Cited by 40
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 41
“PI3K-AKT-mTOR Pathway The mammalian target of rapamycin (mTOR), a kinase in the phosphoinositide-3-kinase (PI3K)/AKT signaling pathway, integrates growth factor stimulation with energy and nutrient signaling to control cell growth and proliferation (Figure 1).(25) In BC, the PI3K/AKT/mTOR pathway modulates responses t…”
BackgroundWright, K. D., Yao, X., London, W. B., Kao, P., Gore, L., Hunger, S. P., Geyer, R., Cohen, K. J., Allen, J. C., Katzenstein, H. M., et al. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28787 · Cited by 41
The Dual Role of Circular RNAs as miRNA Sponges in Breast Cancer and Colon Cancer
Huang, J., Yu, S., Ding, L., Ma, L., Chen, H., Zhou, H., Zou, Y., Yu, M., Lin, J., & Cui, Q. (2021) · Biomedicines · doi:10.3390/biomedicines9111590 · Cited by 42
Gypenoside‐Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer
Li, X., Liu, H., Lv, C., Du, J., Lian, F., Zhang, S., Wang, Z., & Zeng, Y. (2022) · BioMed Research International · doi:10.1155/2022/9304552 · Cited by 49
“The PI3K/AKT/mTOR pathway is a crucial regulator of multiple cellular processes, including motility, growth, metabolism, and angiogenesis [39, 40].”
Zhang, X., Zhang, H.-Y., Zhang, P., Lü, X., & Sun, H. (2008) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.12.021 · Cited by 40
“A vast body of studies has suggested that the aberration of this pathway results in cellular abnormal proliferation, which eventually induces such diseases as cancer and diabetes [16].”
BackgroundFeng, W., Brown, R. E., Trung, C. D., Li, W., Wang, L., Khoury, T., Alrawi, S., Yao, J. C., Xia, K., & Tan, D. (2008) · PubMed · Cited by 40
Evidence for a molecular link between the tuberous sclerosis complex and the Crumbs complex
Massey‐Harroche, D., Delgrossi, M.-H., Lane, L., Arsanto, J., Borg, J., Billaud, M., & Bivic, A. L. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl485 · Cited by 45
Müller, J., Ehlers, A., Burkhardt, L., Sirma, H., Steuber, T. P., Graefen, M., Sauter, G., Minner, S. J. P., Simon, R., Schlomm, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27768 · Cited by 39
“Upon activation, mTOR initiates protein synthesis and cell growth through activation of S6 kinase and eukaryotic initiation factor 4E-binding protein 1.(9) Inhibitors of mTOR, for example rapamycin, that have been widely used to suppress transplant Key words: p-mTOR, TMPRSS2:ERG, PTEN, prostate cancer,”
MethodKouidhi, S., Noman, M. Z., Kieda, C., Elgaaied, A. B., & Chouaib, S. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00114 · Cited by 36
“This alteration activates the PI3K/AKT/mTOR pathway that results in stimulating glucose uptake and glycolysis by affecting activities of key glycolytic enzymes, such as hexokinase (HK) and phosphofructokinase (PFK) (83, 84).”
BackgroundPurple sweet potato anthocyanin exerts antitumor effect in bladder cancer
Li, W., Yu, H., Zhang, X., Ke, M., & Hong, T. (2018) · Oncology Reports · doi:10.3892/or.2018.6421 · Cited by 42
NAFLD Related-HCC: The Relationship with Metabolic Disorders
Zhang, X. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-8684-7_5 · Cited by 41
Larsson, P., Khaja, A. S. S., Semenas, J., Wang, T., Sarwar, M., Dizeyi, N., Simoulis, A., Hedblom, A., Wai, S. N., Ødum, N., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32607 · Cited by 42
DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma
Zhang, G., Tang, X., Liang, L., Zhang, W., Li, D., Li, X., Zhao, D., Zheng, Y., Chen, Y., Hao, B., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1215-6 · Cited by 43
Nutrient Control of mRNA Translation
Shu, X. E., Swanda, R. V., & Qian, S. (2020) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-120919-041411 · Cited by 43
“, Ras, PI3K/mTOR, and MYC) converge to regulate the assembly and activity of eIF4F, a protein complex responsible for ribosome loading to the 5′ end cap of mRNAs (23, 98, 138).”
BackgroundComprehensive review on signaling pathways of dietary saponins in cancer cells suppression
Zhou, Y., Farooqi, A. A., & Xu, B. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.2000933 · Cited by 45
“It positively modulates protein translation through phosphorylating p70S6K and 4E-BP1, and negatively modulates autophagy by phosphorylating serine2448 in mTOR1 (Shaw and Cantley 2006; Zoncu, Efeyan, and Sabatini 2011).”
BackgroundPRAS40: Target or modulator of mTORC1 signalling and insulin action?
Nascimento, E. B. M., & Ouwens, D. M. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450902988580 · Cited by 42
Kodiha, M., Tran, D. H., Morogan, A., Qian, C. X., & Stochaj, U. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008420 · Cited by 44
“both in the nuclear and cytoplasmic compartment [12]; however,”
BackgroundPhosphatidylinositol 3 kinase–Akt signaling serves as a circadian output in the retina
Ko, M. L., Jian, K., Shi, L., & Ko, G. Y. ‐. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05931.x · Cited by 39
Hamza, M. A., & Gilbert, M. R. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0379-z · Cited by 43
Sahin, I. H., Iacobuzio-Donahue, C. A., & O’Reilly, E. M. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1094057 · Cited by 37
“Activation of PIK3CA by K-Ras and other growth stimuli receptors, such as EGFR, promotes cell tumor cell growth and prepares the cell for the next phase of cell cycle progression [8].”
BackgroundRehan, M. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26117 · Cited by 39
Oxidation of retromer complex controls mitochondrial translation
Zhang, J., Ali, M. Y., Chong, H. B., Tien, P.-C., Woods, J., Noble, C., Vornbäumen, T., Ordulu, Z., Possemato, A. P., Harry, S., et al. (2025) · Nature · doi:10.1038/s41586-025-08756-y · Cited by 38
Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.890 · Cited by 40
“[40-55].”
Zhang, X., Liu, M., Wang, Z., Wang, P., Kong, L., Wu, J., Wu, W., Ma, L., Jiang, S., Ren, W., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1417655 · Cited by 50
“Akt is then phosphorylated, which in turn phosphorylates several cellular target proteins, including mTOR and glycogen synthase kinase 3, ultimately promoting cell cycle progression (Shaw and Cantley, 2006).”
BackgroundGenetics and Pharmacology of Longevity
Castillo-Quan, J. I., Kinghorn, K. J., & Bjedov, I. (2015) · Advances in genetics · doi:10.1016/bs.adgen.2015.06.002 · Cited by 38
Genetic Diversity of Hepatocellular Carcinomas and its Potential Impact on Targeted Therapies
Zucman‐Rossi, J., & Laurent‐Puig, P. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.997 · Cited by 40
Smith, L. D., Hickman, E. S., Parry, R. V., Westwick, J. K., & Ward, S. G. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.08.006 · Cited by 41
Tsubaki, M., Itoh, T., Satou, T., Imano, M., Komai, M., Ogawa, N., Mukai, J., & Nishida, S. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.009 · Cited by 38
“Hence, their activation could activate Ras [7].”
BackgroundBrooks, C., Sheu, T., Bridges, K. A., Mason, K. A., Kuban, D. A., Mathew, P. F., & Meyn, R. E. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-154 · Cited by 38
“However, generally, it appears that many if not most TKIs inhibit signaling downstream of growth factor receptors mediated by the PI3K-AKT and Ras-Raf-MEK-ERK pathways [15,16].”
Targeted Therapies: The Rare Cancer Paradigm
Pierotti, M. A., Negri, T., Tamborini, E., Perrone, F., Pricl, S., & Pilotti, S. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.10.003 · Cited by 44
“The presence of activated RTKs leads to the activation of secondary transducers, belonging to the MAPK or PI3K/AKT pathways, which concur in activating mTOR (Shaw and Cantley, 2006).”
BackgroundZhang, J., Riby, J. E., Conde, L., Grizzle, W. E., Cui, X., & Skibola, C. F. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1129-6 · Cited by 38
“mTOR is a critical effector of PI3K signaling in many human cancers [12], and disruption of the pathway results in apoptotic cell death [13, 14].”
BackgroundZeng, Y., Wang, K., Xu, H., & Hong, Y. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26315 · Cited by 38
“As a critical regulator of cell proliferation, growth and translation, mTOR is found to be involved in many cancers.(26,27) Existing evidence suggests mTOR signaling proteins are activated in cervical cancer cell lines and cervical tumors.”
BackgroundThe Isoform Selective Roles of PI3Ks in Dendritic Cell Biology and Function
Aksoy, E., Saveanu, L., & Manoury, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02574 · Cited by 40
Ras signaling is essential for lens cell proliferation and lens growth during development
Xie, L., Overbeek, P. A., & Reneker, L. W. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.06.045 · Cited by 38
“Once Ras is activated, it interacts with several downstream effector proteins and turns on signaling pathways to elicit various biological functions (Campbell et al., 1998; Downward, 1998; Kerkhoff and Rapp, 1998; Shaw and Cantley, 2006).”
BackgroundShi, K., Queiroz, K. C. S., Stap, J., Richel, D. J., & Spek, C. A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12361 · Cited by 38
Induction of Melanogenesis by Rapamycin in Human MNT-1 Melanoma Cells
Hah, Y., Cho, H. Y., Lim, T., Park, D. H., Kim, H. M., Yoon, J., Kim, J. G., Kim, C. Y., & Yoon, T.-J. (2012) · Annals of Dermatology · doi:10.5021/ad.2012.24.2.151 · Cited by 39
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 40
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Cirone, P., Andresen, C. J., Eswaraka, J. R., Lappin, P. B., & Bagi, C. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2376-1 · Cited by 39
“Although activated KRAS can bind to and activate the p110α subunit of PI3K, resulting in the activation of downstream cellular functions [20, 21], we reported that bladder cancer cell lines are less sensitive to the MEK inhibitor PD-0325901 (hereafter PD901) when bearing mutations activating PI3K/AKT/mTOR either direc…”
BackgroundAnagnostou, V., Bepler, G., Syrigos, K. N., Tanoue, L. T., Gettinger, S. N., Homer, R., Boffa, D. J., Detterbeck, F. C., & Rimm, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0099 · Cited by 43
Liu, X., Wang, L., Chen, J., LING, Q., Wang, H., Li, S., Li, L., Yang, S., Xia, M., & Jing, L. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2811 · Cited by 37
“For example, enhanced PI3K/AKT/mTOR activity is linked to the overexpression of c‑myc, vascular endothelial growth factor and hypoxia‑inducible factor‑1 α (24,31).”
Emerging themes of regulation at the Golgi
Makowski, S. L., Tran, T. T. T., & Field, S. J. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.01.004 · Cited by 37
Ji, L., Wu, M., & Li, Z. (2018) · Molecules · doi:10.3390/molecules23082047 · Cited by 37
“mTOR is a remarkable regulator of tumor growth, metastasis, and angiogenesis [32,33].”
BackgroundmTOR-Dependent Role of Sestrin2 in Regulating Tumor Progression of Human Endometrial Cancer
Shin, J., Bae, J., Park, S., Kang, H., Shin, S. M., Won, G., Kim, J.-S., Cho, S., Choi, Y., Oh, S., et al. (2020) · Cancers · doi:10.3390/cancers12092515 · Cited by 37
Decavanadate and metformin-decavanadate effects in human melanoma cells
Sousa‐Coelho, A. L. D., Aureliano, M., Fraqueza, G., Serrão, G., Gonçalves, J., Sánchez‐Lombardo, I., Link, W., & Ferreira, B. I. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2022.111915 · Cited by 37
Heikkinen, T., Korpela, T., Fagerholm, R., Khan, S., Aittomäki, K., Heikkilä, P., BLOMQVIST, C. P., Carpén, O., & Nevanlinna, H. A. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2671-2 · Cited by 37
“The pathways involved in the induction of aberrant translation include PI3K pathway, which is frequently activated in human malignancies through inactivating-mutations in the PTEN gene or activating-mutations in AKT and PIK3CA genes; events considered as strong driver events of carcinogenesis [2].”
BackgroundExpression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas
Scheper, M., Chaisuparat, R., Nikitakis, N. G., & Sauk, J. J. (2008) · Oral Diseases · doi:10.1111/j.1601-0825.2007.01421.x · Cited by 37
Genetic changes in small cell lung carcinoma
Arriola, E., Cañadas, I., Arumí, M., Rojo, F., Rovira, A., & Albanell, J. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0181-1 · Cited by 39
“The activation of this pathway results in increased proliferation and survival of malignant cells [67, 68].”
BackgroundDeguelin promotes apoptosis and inhibits angiogenesis of gastric cancer
Hồng (2010) · Oncology Reports · doi:10.3892/or.2010.957 · Cited by 37
Ye, T., Su, J., Huang, C., Yu, D., Dai, S., Huang, X., Chen, B., & Zhou, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s122653 · Cited by 39
“In many reports, it has been confirmed that mTOR, which is negatively regulated by AMPK, is involved in cancer cell death.(49,50) Similarly, the tumor suppressors TSC2 and p53 are downstream targets of AMPK activity.”
Phosphoinositide 3-kinase signalling and FoxO transcription factors in rheumatoid arthritis
Reedquist, K. A., Ludikhuize, J., & Tak, P. P. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340727 · Cited by 37
The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Engelman, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0653 · Cited by 36
“However, the commonly used PI3K inhibitors, wortmannin and LY294002, inhibit class I, class II (to a lesser extent), and class III PI3Ks as well as other PIK homologues (such as mTOR; ref.”
BackgroundSystems Biology of AGC Kinases in Fungi
Sobko, A. (2006) · Science's STKE · doi:10.1126/stke.3522006re9 · Cited by 36
The mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Next-generation Inhibitors and Approaches
Ihlamur, M., Akgül, B., Zengin, Y., Korkut, Ş. V., Kelleci, K., & Abamor, E. Ş. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230509161645 · Cited by 40
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.